<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03897374</url>
  </required_header>
  <id_info>
    <org_study_id>02252019</org_study_id>
    <nct_id>NCT03897374</nct_id>
  </id_info>
  <brief_title>Strategic Targeting for Optimal Prevention of Cancer</brief_title>
  <acronym>STOP-Cancer</acronym>
  <official_title>Strategic Targeting for Optimal Prevention of Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ClinLogic LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ClinLogic LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of the study is to record data over the observation period to evaluate the&#xD;
      clinical benefit of using hereditary cancer genomic diagnostics to assess overall hereditary&#xD;
      genetic cancer risk profile and to help guide physicians to pursue preventative measures,&#xD;
      which may lead to early detection and treatment of the condition.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data collection will be limited to study subjects 65 years or older. The genes evaluated may&#xD;
      be modified from time to time by the Sponsor as the body of knowledge expands and important&#xD;
      additional pathways are identified. The list of appropriate genes that may be considered by&#xD;
      the treating physician includes but are not necessarily limited to the following genes: ATM,&#xD;
      BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MRE11A, MSH2, MSH6, NBN, PALB2, PMS2,&#xD;
      PTEN, RAD50, RAD51C, RAD51D, RINT1, TP53 and XRCC2. These subjects must also meet medical&#xD;
      necessity for hereditary cancer genomic testing; and allow physician to test based on medical&#xD;
      necessity. Hereditary Cancer testing will be diagnostic rather than screening in nature.&#xD;
&#xD;
      Study subject data will be collected only if medical necessity was established, subject&#xD;
      agreed to test based on medical necessity and hereditary cancer genomic test was ordered by a&#xD;
      physician related to individual study subject care considerations. The hereditary Cancer&#xD;
      testing is independent of this data-collection, non- interventional study. The hereditary&#xD;
      cancer genomic test must be ordered according to the individual study subject care&#xD;
      considerations, it is not protocol specified, and will not be considered as &quot;research&quot; that&#xD;
      is part of the study. Rather, the use of hereditary cancer genomic testing serves as criteria&#xD;
      for eligibility in the study and must have been ordered for medical necessity and results&#xD;
      received no less than 90 days prior before data is collected.&#xD;
&#xD;
      The primary goal of the study is to record data over the observation period to evaluate the&#xD;
      clinical benefit of using hereditary cancer genomic diagnostics to assess overall hereditary&#xD;
      genetic cancer risk profile and to help guide physicians to pursue preventative measures,&#xD;
      which may lead to early detection and treatment of the condition; and to record physician&#xD;
      recommended treatments and subject's brief medical history, demographic data; and&#xD;
      investigator specialty.&#xD;
&#xD;
      Such genetic test results and recommended treatments can be tabulated and analyzed to&#xD;
      demonstrate the clinical utility of using hereditary cancer genomic diagnostics for&#xD;
      prevention, early detection and treatment of the condition.&#xD;
&#xD;
      The data will be collected retrospectively for a total of 120 no more than 150 days over the&#xD;
      observation period in one (1) Case Report Form (survey). Similarly, the secondary objectives&#xD;
      will be tabulated over the same observation period.&#xD;
&#xD;
      An interim analysis of data will be performed to determine if the study subject data&#xD;
      collection should be increased or decreased in order to fulfill study objectives.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 26, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>120 Days</target_duration>
  <primary_outcome>
    <measure>Genomic cancer screen</measure>
    <time_frame>120 Days</time_frame>
    <description>A study subject is known to have personal and/or family history of cancer known to be influenced by genetic variation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genomic cancer screen</measure>
    <time_frame>120 Days</time_frame>
    <description>A genotype known to be a predisposition for cancer.</description>
  </primary_outcome>
  <enrollment type="Anticipated">120000</enrollment>
  <condition>Early Detection of Cancer</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Genetic Testing</intervention_name>
    <description>Buccal swab</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals, ages 65 years or older.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Study subjects may be included in the Clinical Trial if they meet all of the following&#xD;
             inclusion criteria:&#xD;
&#xD;
               -  individuals, ages 65 years or older;&#xD;
&#xD;
               -  must have met medical necessity for hereditary cancer genomic testing and allowed&#xD;
                  the physician to test based on medical necessity;&#xD;
&#xD;
               -  hereditary cancer diagnostic test was ordered by a physician related to&#xD;
                  individual subject care considerations.&#xD;
&#xD;
               -  hereditary cancer diagnostic test was received no more than 90 days prior to data&#xD;
                  collection.&#xD;
&#xD;
        one or more of the following must be present:&#xD;
&#xD;
          -  study subject has more than one cancer; or&#xD;
&#xD;
          -  study subject has multiple close family members with a cancer diagnosis under the age&#xD;
             of fifty; or&#xD;
&#xD;
          -  study subject has three or more close family members with different types of cancer;&#xD;
             or&#xD;
&#xD;
          -  study subject has had family that has previously had cancer genetics testing and&#xD;
             mutations were identified.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Study subjects will be excluded from the study if any of the following criteria apply:&#xD;
             â€¢ study subject is currently hospitalized or incarcerated;&#xD;
&#xD;
               -  study subject's medical and medication history is unavailable over the 90-days&#xD;
                  preceding and following data collection;&#xD;
&#xD;
               -  study subject is unable to provide an accurate history due to mental incapacity&#xD;
&#xD;
               -  study subject is currently abusing illicit and/or prescription drugs;&#xD;
&#xD;
               -  study subject is known to have undergone prior hereditary cancer diagnostic&#xD;
                  testing for genes specific to the targeted genes, exclusive of the CGx test&#xD;
                  relating to the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Diana Messir</last_name>
    <phone>833-226-7545</phone>
    <email>Diana@integritycro.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sunbeam Clinical</name>
      <address>
        <city>Prosper</city>
        <state>Texas</state>
        <zip>75078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kiran Asma</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>March 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2019</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

